Relay Therapeutics has been granted a patent for crystalline forms of a specific compound, including its salt and variants. Claim 1 specifically covers a solid form of Compound I-1. GlobalData’s report on Relay Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Premium Insights Relay Therapeutics Inc - Company Profile

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Relay Therapeutics, Targeted cancer therapy was a key innovation area identified from patents. Relay Therapeutics's grant share as of February 2024 was 10%. Grant share is based on the ratio of number of grants to total number of patents.

Solid form of compound i-1

Source: United States Patent and Trademark Office (USPTO). Credit: Relay Therapeutics Inc

The granted patent (Publication Number: US11890281B2) discloses a solid form of Compound I-1, which can be either crystalline or amorphous. The crystalline form is characterized by specific XRPD patterns and DSC profiles, making it distinguishable. Additionally, the patent claims a compound of Formula (I), which can also exist in amorphous or crystalline forms with distinct XRPD patterns.

Furthermore, the patent includes methods for inhibiting SHP2 phosphatase activity and treating disorders mediated by SHP2 by administering the solid form of Compound I-1 or its pharmaceutically acceptable salt. The disorders mentioned range from Noonan syndrome to various types of cancers like melanoma, breast cancer, lung cancer, and colorectal cancer. The patent also covers a process for preparing the crystalline form of Compound I-1, involving specific steps like dissolving the compound in a solvent and isolating the crystalline form. Additionally, a kit containing the solid form of Compound I-1 and instructions for administering a pharmaceutical composition prepared using it is also part of the patent.

To know more about GlobalData’s detailed insights on Relay Therapeutics, buy the report here.

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies